Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Abbott wins CE mark for new LAA closure device

29 August 2026 · By · Wire by Fusion42

Published

29 August 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

Europe

◆ Source

Read at medtechdive.com →

◆ Verified

Fusion42 · 29 August 2026 · Fusion42 review

Abbott has secured CE mark approval for its new left atrial appendage (LAA) closure device, positioning itself to compete with Boston Scientific in the stroke risk reduction market.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

You face a new competitor disrupting the LAA closure device market in Europe. Consider how Abbott’s CE mark could shift purchasing decisions and open doors beyond established suppliers.

◆ Coverage

1 source · 29 Aug 2026

◆ Related on Wire

◆ Topics

MedtechCE-markmedical-deviceLAA-closurestroke-preventionAbbottBoston-Scientific